Clinical trials in Caen – page 20

649 clinical trials in Caen, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Caen at a glance

649

clinical trials

Research sites3

Quick filters

649 trials in Caen

Open in trial search

Breast cancer+2

Recruiting

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Institut Gustave Roussy

Contact Research Centre

Retinoblastoma

Recruiting

Study on Retinoblastoma Treatment: Evaluating the Effectiveness of Topotecan, Vincristine Sulfate, and Etoposide in Patients Eligible for Conservative Therapy

Registered drugNo placebo

Study on Retinoblastoma Treatment: Evaluating the Effectiveness of Topotecan, Vincristine Sulfate, and Etoposide in Patients Eligible for Conservative Therapy

Registered drugNo placebo

France

Participants:0–17 years
Substances:Carboplatin
Sponsor:Institut Curie

Contact Research Centre

Metastases to central nervous system

Recruiting

Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

Registered drug

Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Institut De Cancerologie De L Ouest

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Darolutamide
Sponsor:Unicancer

Contact Research Centre

Adenocarcinoma gastric+4

Recruiting

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Plasma cell myeloma

Recruiting

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cardiac failure

Recruiting

Study on Stopping Beta-Blockers in Heart Failure Patients with Recovered Heart Function Using Carvedilol and Drug Combination

Registered drugNo placebo

Study on Stopping Beta-Blockers in Heart Failure Patients with Recovered Heart Function Using Carvedilol and Drug Combination

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Hydrochlorothiazide
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Adding Sulfasalazine, Idarubicin, and Cytarabine to Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia in Patients Aged 60 and Older

Registered drugNo placebo

Study on Adding Sulfasalazine, Idarubicin, and Cytarabine to Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia in Patients Aged 60 and Older

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Neuroendocrine cell hyperplasia of infancy

Recruiting

Study on the Effects of Methylprednisolone in Infants with Neuroendocrine Cell Hyperplasia

Registered drugNo placebo

Study on the Effects of Methylprednisolone in Infants with Neuroendocrine Cell Hyperplasia

Registered drugNo placebo

France

Participants:0–17 years
Substances:Methylprednisolone
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Anti-neutrophil cytoplasmic antibody positive vasculitis

Recruiting

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Caen

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on multiple cancer types including head and neck squamous cell carcinoma, endometrial cancer, and multiple myeloma. Studies evaluate novel therapeutic combinations and treatment strategies.

Advanced solid tumors
Hematological malignancies
Gastrointestinal cancers

Trials investigate targeted therapies and immunotherapy approaches for improved patient outcomes.

02 Infectious Disease Research

Studies examining prevention and treatment of respiratory infections, with focus on respiratory syncytial virus (RSV) in vulnerable populations. Investigation of novel antibiotics for prosthetic joint infections.

Viral infections
Bacterial infections
Preventive treatments

Research aims to develop effective preventive strategies and therapeutic interventions.

03 Cardiovascular Medicine

Research exploring treatments for heart failure prevention and management of cardiovascular conditions. Studies evaluate antiplatelet therapy strategies in elderly patients following interventional procedures.

Heart failure
Coronary interventions
Preventive cardiology

Focus on improving cardiovascular outcomes through innovative therapeutic approaches.

Back to France All countries